Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level

Bioscience, Biotechnology and Biochemistry

Volumn 72, Issue 10, 2008, Pages 2623-2631

  Batovska, Daniela I ^a,c   Kim, Dong Hoon ^b   Mitsuhashi, Shinya ^a   Cho, Yoon Sun ^b   Kwon, Ho Jeong ^b   Ubukata, Makoto ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Yonsei University   (South Korea)

^c INSTITUTE OF ORGANIC CHEMISTRY   (Bulgaria)

Author keywords

tubulin deacetylase (TDAC); HDAC inhibitors synthesis; Histone deacetylase (HDAC); Inosine monophosphate dehydrogenase (IMPDH); Mycophenolic acid (MPA)

Indexed keywords

BINDING ENERGY; BINDING SITES; CELL PROLIFERATION; ENZYMES; ORGANIC ACIDS;

CELLULAR LEVELS; CLINICAL TRIALS; HDAC INHIBITORS SYNTHESIS; HISTONE DEACETYLASE; HISTONE DEACETYLASE (HDAC); HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH); MULTIPLE MYELOMATA; MYCOPHENOLIC ACID (MPA); MYCOPHENOLIC ACIDS;

ACIDS;

DRUG DERIVATIVE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; MYCOPHENOLIC ACID;

ARTICLE; CELL MOTION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MOLECULAR STRUCTURE; MYCOPHENOLIC ACID;

EID: 55049101683     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.80303     Document Type: Article

References (36)

1. Birkinshaw, J. H., Raistrick, H., and Ross, D. J., The molecular constitution of mycophenolic acid, a metabolite of Penicillium brevi-compactum DIERCKX. III. Further observations on the structural formula for mycophenolic acid. Biochem. J., 50, 630-634 (1952).
2. Arns, W., Cibrik, D. M., Walker, R. G., Mourad, G., Budde, K., Mueller, E. A., and Vincenti, F., Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation, 82, 1004-1012 (2006).
3. Konno, Y., Natsumeda, Y., Nagai, M., Yamaji, Y., Ohno, S., Suzuki, K., and Weber, G., Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemia cell lines. J. Biol. Chem., 266, 506-509 (1991).
4. Nagai, M., Natsumeda, Y., Konno, Y., Hoffman, R., Irino, S., and Weber, G., Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res., 51, 3886-3890 (1991).
5. Natsumeda, Y., Ohno, S., Kawasaki, H., Konno, Y., Weber, G., and Suzuki, K., Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem., 256, 5292-5295 (1990).
6. Ubukata, M., Takamori, H., Ohashi, M., Mitsuhashi, S., Yamashita, K., Asada, T., Nakajima, N., Matsuura, N., Tsuruga, M., Taki, K., and Magae, J., Mycophenolic acid as a latent agonist of PPARγ. Bioorg. Med. Chem. Lett., 17, 4767-4770 (2007).
7. Floryk, D., Tollaksen, S. L., Giometti, C. S., and Huberman, E., Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′-monophosphate dehydrogenase. Cancer Res., 64, 9049-9056 (2004).
8. Floryk, D., and Huberman, E., Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity. Cancer Res., 65, 11588-11596 (2005).
9. Floryk, D., and Huberman, E., Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145. Cancer Lett., 231, 20-29 (2006).
10. Chong, C. R., Qian, D. Z., Pan, F., Wei, Y., Pili, R., Sullivan Jr., D. J., and Liu, J. O., Identification of type I inosine monophosphate dehydrogenase as an antiangiogenic drug target. J. Med. Chem., 49, 2677-2680 (2006).
11. Takabe, N., Cheng, X., Wu, S., Bauer, K., Goloubeva, O. G., Fenton, R. G., Heyman, M., Rapoport, A. P., Badros, A., Shaughnessy, J., Ross, D., Meisenberg, B., and Tricot, G., Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin. Cancer Res., 10, 8301-8308 (2004).
12. Takabe, N., Cheng, X., Fandy, T. E., Srivastava, R. K., Wu, S., Shankar, S., Bauer, K., Shaughnessy, J., and Tricot, G., IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol. Cancer Ther., 5, 457-466 (2006).
13. Strahl, B. D., and Allis, C. D., The language of covalent histone modifications. Nature, 403, 41-45 (2000).
14. Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., and Pelicci, P. G., Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med., 11, 71-76 (2005).
15. Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., Weosz, A., de Lera, A. R., Gronemeyer, H., and Altucci, L., Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 11, 77-84 (2005).
16. Liu, T., Kuljaca, S., Tee, A., and Marshall, G. M., Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev., 32, 157-165 (2006).
17. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., and Richon, V. M., Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cells in vitro and in vivo. Cancer Res., 60, 5165-5170 (2000).
18. Pauer, L., Olivares, J., Cunningham, C., Williams, A., Grove, W., Kraker, A., Olson, S., and Nemunaitis, J., Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest., 22, 886-896 (2004).
19. Richards, D. A., Boehm, K. A., Waterhouse, D. M., Wagener, D. J., Krishnamurthi, S. S., Rosemurgy, A., Grove, W., Mackonald, K., Gulyas, S., Clark, M., and Dasse, K. D., Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol., 17, 1096-1102 (2006).
20. Marshall, J. L., Riizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Li, M. Z., and Hawkins, M. J., A phase I trial of depisipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol., 2, 325-332 (2002).
21. Yoshida, M., Kijima, M., Akita, M., and Beppu, T., Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265, 17174-17179 (1990).
22. Haggarty, S. J., Koeller, K. M., Wong, J. C., Butcher, R. A., and Schreiber, S. L., Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol., 10, 383-396 (2003).
23. Finnin, M. S., Donigian, J. R., Cohen, A., Rchon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., and Pavletich, N. P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-193 (1991).
24. Ubukata, M., Batovska, D. I., Takamori, H., Mitsuhashi, S., Matsuura, N., Yamashita, K., Asada, T., Nakajima, N., Mage, J., Kim, D., and Kwon, H. J., Mycophenolic acid and its analogs, development of ligands of PPARs and HDAC inhibitors, Pacifichem (CD ROM), December 17, Hawaii (2005).
25. Cheng, L., Wilson, D., Jayaram, H. N., and Pankiewicz, K. W., Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J. Med. Chem., 50, 6685-6691 (2007).
26. Kim, D. H., Shin, J., and Kwon, H. J., Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med., 39, 47-55 (2007).
27. Reddy, A. S., Kumar, S., and Reddy, R., A convenient method for the preparation of hydroxamic acids. Tetrahedron Lett., 41, 6285-6288 (2000).
28. Lee, W. A., Gu, L., Miksztal, A. R., Chu, N., Leung, K., and Nelson, P. H., Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm. Res., 7, 161-166 (1990).
29. Tran, A. D., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., Sheetz, M. P., Yao, T. P., and Bulinski, J. C., HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesion. J. Cell Sci., 120, 1469-1479 (2007).
30. Remiszewski, S. W., Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Discov. Devel., 5, 487-499 (2002).
31. McPhillips, C. C., Hyle, J. W., and Reines, D., Detection of the mycophenolate-inhibited form of IMP dehydrogenase in vivo. Proc. Natl. Acad. Sci. USA, 101, 12171-12176 (2004).
32. Ji, Y., Gu, J., Makhov, A. M., Griffith, J. D., and Mitchell, B. S., Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J. Biol. Chem., 281, 206-212 (2006).
33. Hedstrom, L., and Gan, L., IMP dehydrogenase: structural schizophrenia and an unusual base. Curr. Opin. Chem. Biol., 10, 520-526 (2006).
34. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., and Yao, T.-P., HDAC6 is a microtubule-associated deacetylase. Nature, 417, 455-458 (2002).
35. Sjogrren, E. B., U.S. Patent, 5380879 (Jan. 10, 1995).
36. Marks, P. A., Discovery and development of SAHA as an anticancer agent. Oncogene, 26, 1351-1356 (2007).